Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Earnings

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

By The Northwire Desk — AI Analysis Mar 12, 2026 · 21:03 EPRX · 10.21 EUPRAXIA PHARMACEUTICALS INC. J
EPRX · Price

Executive Summary

  • Eupraxia Pharmaceuticals reported Q4 2025 net loss of $16.7 M, but cash on hand rose to $80.5 M driven by a $63.2 M public offering completed on Feb 20 2026.
  • The company disclosed positive clinical readouts from the RESOLVE trial in eosinophilic esophagitis (EoE), including 52‑week follow‑up data and near‑complete biopsy improvement.
  • Management indicated that existing cash, proceeds from the offering, and anticipated warrant exercises are expected to fund operations into the second half of 2028.

Key Details

  • Financing: Closed a public offering of 7,607,145 common shares at $7.00 per share; gross proceeds ≈ $63.2 M. Included full exercise of underwriters’ option for 1,178,571 additional shares and issuance of 1,428,571 pre‑funded warrants at $6.99999 each.
  • Cash Position: $80.5 M as of Dec 31 2025 (up from $33.1 M at end of Q4 2024).
  • Share Count: 51,939,206 common shares and 8,355,638 preferred shares outstanding as of Dec 31 2025.
  • Net Loss: $16.7 M for Q4 2025 vs. $7.5 M for Q4 2024; increase driven by higher R&D spend on EP‑104GI and higher G&A expenses.
  • Clinical Milestones – RESOLVE Trial (EoE):
  • Nov 13 2025: 52‑week follow‑up data showed consistent results post‑dosing with EP‑104GI.
  • Jan 8 2026: Positive tissue health data demonstrated near‑complete improvement on biopsy.
  • Runway Outlook: Existing cash plus offering proceeds and expected in‑the‑money warrant exercises projected to fund the company through H2 2028.
  • Tariff Monitoring: Management is assessing potential impacts of U.S./Canadian tariff changes on supply chain and costs; no material effect identified to date.

Notable Quotes

“2025 was a pivotal year for Eupraxia… we achieved significant clinical milestones… and strengthened our balance sheet with two recent financings, positioning us well for our next phase of growth.” – James Helliwell, CEO

All forward‑looking statements are subject to risks and uncertainties detailed in the release.

Read the original news release →

More from EUPRAXIA PHARMACEUTICALS INC. J

May 12, 2026 · 17:00

Eupraxia Pharmaceuticals Secures H2 2028 Runway with Strong Clinical Data, But Phase 2b Catalyst Remains Key

Earnings May 06, 2026 · 07:00

Eupraxia Confirms Fibrosis Reversal in EoE, But Phase 2b Readout Remains Key Catalyst

Other May 05, 2026 · 07:00

Eupraxia Confirms Dose-Response in EoE Trial; Phase 2b Data Due Q4

Other Apr 22, 2026 · 07:00

Eupraxia Confirms Durable Efficacy and Safety Profile Ahead of Phase 2b Top-Line Readout

Other Apr 21, 2026 · 07:00

Eupraxia Durability Data Validates Lead Candidate, Yet Phase 2b Timing Shifts to Q4

Other Mar 17, 2026 · 12:41

Eupraxia posts 24-week data in high-dose Resolve cohort

Other